Assembly Biosciences, Inc. (ASMB) Stock Price Quote, News…

Summary

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Website

www.assemblybio.com

Location

South San Francisco, CA, US

Phone833 509 4583

Employees73

CEOJason A. Okazaki

Sector

Health Care

Industry

Pharmaceuticals

IPO DateDec 17, 2010

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… association with decreasing levels of HBsAg and/or markers of immune activation • Patients were dosed in intervals of 4, 8 or 12 weeks, which optimizes convenience \*Includes 49 patients dosed with imdusiran in Assembly Biosciences, Inc.'s A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI - H0731) in Participants With Chronic Hepatitis B Infection 1. Varughese et al., Poster 1160, AASLD 2025 © 2026 ARBUTUS BIOPHARMA, INC 13 AB - …
Arbutus Biopharma CorpAssembly Biosciences, Inc.·EX-99.1 - 8-K - Other Events·Q4 26·12 Nov
… proved as a second-line treatment for PBC in patients with inadequate response to UDCA. We are aware of several agents in clinical development for the treatment of PBC including Alfasigma’s Ocaliva and bezafibrate, Assembly Biosciences Inc.’s ABI-6250, Zydus Therapeutics Inc.’s saroglitazar magnesium, Calliditas Therapeutics AB’s setanaxib, COUR Pharmaceuticals’ CNP-104, Umecrine Cognition’s golexanolone, Kowa Company Ltd’s K-808, HighTide Therap …
Mirum Pharmaceuticals, Inc.Assembly Biosciences, Inc.·10-Q - Quarterly report Q3·Q3 26·3 Nov
… Dermatology Portfolio Leader. Dr. Johnson-Pratt served on the board of TRACON Pharmaceuticals, then a publicly-held company, from March 2021 to September 2024. Dr. Johnson-Pratt currently serves on the board of Assembly Biosciences, Inc., a biopharmaceutical company where she was first elected to the board in May 2021. Dr. Johnson-Pratt received her B.S. and M.D. from Howard University, with further post-doctoral training in Internal Medicine, C …
Aspen Neuroscience, Inc.Assembly Biosciences, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·30 Oct
… ) $2.5M upfront; up to $25M milestones plus royalties. (BioSpace) Phase 2/3 Phase 3 program did not meet superiority vs vancomycin; Summit later focused its strategy on oncology (ivonescimab). (Fierce Biotech) 2017 Assembly Biosciences Allergan (later AbbVie) Microbiome GI programs (often cited as ABI-M201, ABI- M301; not CDI specific) $50M upfront plus milestones and royalties (per deal announcement coverage). (BioSpace) Preclinical Partnership …
Immuron LtdAssembly Biosciences, Inc.·EX-99.1 - 6-K - EMERGING GROWTH CONFERENCE PRESENTATION·Q2 27·28 Oct
… gement. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previously served on the board of director …
Zymeworks Inc.Assembly Biosciences, Inc.·ARS - Annual report to security holders·FY25·26 Oct
… Dermatology Portfolio Leader. Dr. Johnson-Pratt served on the board of TRACON Pharmaceuticals, then a publicly-held company, from March 2021 to September 2024. Dr. Johnson-Pratt currently serves on the board of Assembly Biosciences, Inc., a biopharmaceutical company where she was first elected to the board in May 2021. Dr. Johnson-Pratt received her B.S. and M.D. from Howard University, with further post-doctoral training in Internal Medicine, C …
Aspen Neuroscience, Inc.Assembly Biosciences, Inc.·S-1/A - Registration statement (general form, amendment)·Q4 26·26 Oct

Key Stats

Trading

Px/Chg 1D$22.54 / -1.91%

Prev Close$36.60

% of 52Wk H88.84%

Avg Volume157.09K

Beta1.21

Mkt Cap446.68M

FD Mkt Cap699.15M

Float

Shrs Out/Float19.82M / 12.47M

Short Float0.27%

Days to Cover6.59

Stock Repurchased$0.00

Current Valuation

EV418.05M

EV/EBITDA-58.42

EV/Sales5.88

P/B2.25

P/S6.28

FCF Yield-4.95%

ROE-4.57%

ROA-3.86%

Current Ratio6.65

Estimates

P/E-69.98

Est P/E0.00

Est EPS-0.73

Est PEG0.00

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-7.34	-0.52	-0.94	-1.85	15.92	-49.29
Price / Sales	14.69	0.00	8.06	2.61	8.28	54.48
Price / Book Value	1.64	0.59	1.41	2.23	1.70	2.25
Price / Free Cash Flow	1.01	-0.57	2.57	-1.46	24.74	-20.23
ENTERPRISE VALUE METRICS
Enterprise Value	158.7	-0.5	40.3	39.3	295.8	418.8
Enterprise Value / Sales	12.99	0.00	5.62	1.38	6.96	51.00
Enterprise Value / EBITDA	-6.88	0.01	-0.63	-0.87	13.37	-46.27
Enterprise Value / EBIT	-6.85	0.01	-0.62	-0.86	13.39	-46.13

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	84.4%	6.3	-	7.2	28.5	72.3
Gross Income	84.3%	6.3	-69.1	-41.7	28.5	72.2
EBITDA	-49.3%	-90.6	-92.5	-64.2	-45.3	-6.0
EBIT	-49.1%	-91.1	-93.0	-64.6	-45.4	-6.1
Net Income	-53.4%	-129.9	-93.1	-61.2	-40.2	-6.1
EPS (Diluted)	-64.8%	-36.00	-22.82	-13.38	-6.69	-0.55
BALANCE SHEET
Cash & ST Inv	14.1%	146.6	91.6	130.2	112.1	248.1
Total Assets	7.8%	191.1	101.8	136.8	119.2	257.6
Total Liabilities	23.1%	22.1	19.1	95.7	85.8	50.8
Total Shareholder Equity	5.2%	168.9	82.7	41.1	33.4	206.8
CASH FLOW
Net Operating Cash Flow	-18.6%	-93.4	-84.5	22.7	-51.1	-41.1
Cap Ex	-61.8%	-3.1	-0.1	-0.3	-0.0	-0.1
Free Cash Flow	-19.2%	-96.5	-84.6	22.5	-51.1	-41.2

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		19.80
Basic Shares		19.82
Market Cap		392.4
Diluted Shares		18.85
Fully Diluted Shares Outstanding		18.85
Fully Diluted Market Cap		373.3
+Consolidated Debt		2.4
−In-the-Money Convertible Debt		—
+Capital Leases		2.4
+Operating Leases		—
−Cash & Equivalents		-32.3
−Short-term Investments		-288.1
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		362.4

Related companies